Latest From HOPA

An oncology pharmacist helping a patient
Advocacy

Oncology Pharmacist Survey: Understanding Task Value and Professional Satisfaction

Recent publications have explored workload and productivity to improve oncology pharmacy practice. HOPA aimed to build upon that research by assessing task valuation.

Oncology Pharmacist Day image
Membership

Oncology Pharmacist Day: Celebrating the People Who Make the Profession

On April 3, 2026, the oncology pharmacy community will mark the first-ever Oncology Pharmacist Day, a new annual observance recognizing the essential role hematology/oncology pharmacists play in improving the lives of people affected by cancer.

An image of multiple myeloma cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.

An image of chronic lymphocytic leukemia cells under a microscope
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Cristina V. Martinez, PharmD, PGY2 Oncology Pharmacy Resident, and Hunter Sowell, PharmD, BCOP, Clinical Pharmacy Specialist Oncology, analyze the potential role for pirtobrutinib in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.

A photo of three pharamcists smiling
Collaborations

Pharmacy Students and Oncology Pharmacists Combat Cancer Misinformation with National Initiative

The Hematology/Oncology Pharmacy Association (HOPA) is proud to team up with the Student National Pharmaceutical Association (SNPhA) for the Cancer Clarity Challenge, a new national competition.

An image of the Capitol building on a cloudless day
Advocacy

Congress Passes Health Extenders and PBM Reform

Here's what HOPA members should know about the end of the recent government shutdown, the resulting appropriations bills passed by Congress, and what the package includes pertaining to health care.

A doctor's hands holding an image of lungs
HOPA News Late Breaking News

Late-Breaking HOPA News: NeoADAURA: Advancing Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP, breaks down the results from the NeoADAURA trial and what its findings may mean for neoadjuvant osimertinib's role in the treatment of resectable EGFR-mutated NSCLC.

The numbers 2025 with images of HOPA Hill Day and HOPA Annual Conference filling in the space
Membership

As 2026 Forges Ahead, A Look Back at HOPA in 2025

2025 certainly brought challenges both new and familiar to HOPA, our members, our patients, and those dear to them. But it's also brought hope. It's brought progress. And it's brought an inspiring sense of purpose, passion, and community.

Nurse sitting in hospital hallway resting against a wall
Advocacy

Proposed Student Loan Limits for Nursing and Other Professions Will Contribute to Healthcare Worker Shortages

HOPA is concerned about the Department of Education's proposed language and student loan limits for professions crucial to oncology care, especially nursing. Implementation will contribute to the shortage of healthcare workers in this country.

A graphic of a man's lungs on a blue background
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Taletrectinib

Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.

An image of a doctor looking at an x-ray of lungs with cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zongertinib

Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.

A line of women with breast cancer ribbons on their chests
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Imlunestrant

Chan Tae Park, PharmD, PGY1 Pharmacy Resident, and Andrew Li, PharmD, BCOP, Oncology Pharmacist, dig into the potential role of imlunestrant (Inluriyo) in treating ESR1-mutated advanced/metastatic ER+, HER2- breast cancer.